SAN DIEGO and EDINBURGH, Scotland, Sept. 7, 2016 /PRNewswire/ -- Dexcom, Inc.,
(NASDAQ:DXCM), announced that Germany's Federal Joint Committee
(G-BA) will provide reimbursement for Dexcom's Continuous Glucose
Monitoring (CGM) Systems for patients with insulin-dependent type 1
and type 2 diabetes. The policy change was approved by Germany's Ministry of Health and has now been
initiated.
This decision by the G-BA will open the door for many patients
to benefit from the advanced CGM technology and help them gain
better control of their diabetes. The new reimbursement
policy in Germany only covers
technologies that provide alarms and alerts about glucose levels –
including the Dexcom CGM System.
"We are thrilled that Dexcom CGM Systems are now accessible and
affordable to patients throughout Germany," said Kevin
Sayer, President and Chief Executive Officer of Dexcom.
"This ground-breaking technology plays a vital role for people with
diabetes who are insulin-dependent, allowing them to self-monitor
their condition, manage their glucose levels and reduce risk of
severe hyper or hypoglycemic events."
The Dexcom G5® Mobile CGM System and Dexcom
G4® PLATINUM will be included among the CGM devices that
will be reimbursed by Germany's
Medical Department of the Central Federal Association of Health
Insurance Funds. With 288 glucose readings per day, patients using
the Dexcom G5 Mobile CGM System can see their glucose levels and
make treatment decisions based on the speed and direction of their
readings.1 It also gives patients the added convenience
of seeing their readings directly on their mobile
device.2 G5 Mobile allows patients to share their
glucose readings with up to five friends and family, which provides
an additional layer of support for patients.
"This is a major win for patients with diabetes in Germany," said Rudolf
Messer, MD, Country Manager, Germany. "Before the new ruling took effect,
Germany's strict reimbursement
policies prevented many people with diabetes from benefitting from
CGM, so only a small subset of the insulin-dependent diabetic
population in Germany had access
to this important and potentially life-saving technology. Now
countless people with diabetes, along with their family members and
loved ones, will have access to innovative, quality tools to help
manage their condition."
Germany is the single largest
market in Europe for type 1 and
type 2 diabetes, with nearly 6.6 million people living with the
disease, according to the International Diabetes
Federation.3
About Dexcom, Inc.
Dexcom, Inc., headquartered in
San Diego, California, USA, is
dedicated to helping people better manage their diabetes by
developing and marketing continuous glucose monitoring (CGM)
products and tools for adult and pediatric patients. With
exceptional performance, patient comfort and lifestyle flexibility
at the heart of its technology, users have consistently ranked
Dexcom highest in customer satisfaction and loyalty*. For more
information on the Dexcom CGM, visit www.dexcom.com.
*dQ&A patient surveys, 2009-2016
Cautionary Statement Regarding Forward Looking
Statements
This press release contains forward-looking
statements that are not purely historical regarding Dexcom's or its
management's intentions, beliefs, expectations and strategies for
the future, including those relating to the intended use and
technical specifications of the CGM products, the potential impact
on outcomes associated with diabetes care. Because such
statements deal with future events, they are subject to various
risks and uncertainties, and actual results could differ materially
from Dexcom's current expectations. Factors that could cause actual
results to differ materially include risks and uncertainties such
as those relating to: the inability to successfully development new
products and obtain regulatory approval; a lack of acceptance in
the marketplace by physicians and patients; the inability to
manufacture products in commercial quantities at an acceptable
cost; possible delays in the company's development programs; the
inability of patients to receive reimbursement from third-party
payors; and inadequate financial and other resources. Certain
of these risks and uncertainties, in addition to other risks, are
more fully described in the section entitled "Risk Factors" in
Dexcom's Annual Report on Form 10-K, its most recent Quarterly
Report on Form 10-Q, and its other reports filed with the
Securities and Exchange Commission.
MEDIA CONTACT:
Caren Begun, 856-424-2023
To view multimedia assets, please visit:
http://www.dexcom.com/media
INVESTOR CONTACT:
Steven Pacelli, 858-200-0200
References
- Dexcom G5 Mobile Continuous Glucose Monitoring System, User's
Guide, 2015
- For a list of compatible smartphones, visit
Dexcom.com/compatibility
- International Diabetes Federation. Diabetes in Germany.
http://www.idf.org/membership/eur/germany. Accessed August 25, 2016.
Logo - http://photos.prnewswire.com/prnh/20150811/257482LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/reimbursement-of-dexcom-cgm-technology-for-patients-with-type-1-and-type-2-insulin-dependent-diabetes-is-now-available-in-germany-300324182.html
SOURCE Dexcom, Inc.